Clinical Competition Candidate
ERIVEDGE
ERIVEDGE carries substance and product and use-code patents, low complexity (1/5), and meaningful clinical competition (5/5). The listed expiry window is approximately 29 months away. Active clinical competition may compress the generic entry window.
LOE window
29months
to latest listed patent expiry (December 15, 2028)
Expiry attractiveness: 5/5
Patent profile
Substance patent (listed)
Product / formulation patent (listed)
Use-code patent (listed)
Patent count: 2
Complexity score: 1/5
Clinical competition
Score: 5/5
Active trials linked: 92
Phase 2/3 trials: 61
Higher scores indicate more trial activity for this ingredient — a proxy for competitive generic interest.
Drug overview
Active ingredient: VISMODEGIB
Applicant (NDA holder): GENENTECH INC
Confidence: High